Work

Oral Acarbose Inhibits Baseline Salivary Amylase and Blunts Early Postprandial Glycemia: Randomized Cross-Over Study

Year: 2026

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Abstract: This study investigated whether salivary α-amylase (SAA) inhibition by acarbose affects postprandial blood glucose (BG) in healthy individuals. This single-blinded, placebo-controlled, randomized cross-over trial included 4 conditions: trial 1 (T1), placebo (oligosaccharide); trial 2 (T2), swallowing 50 mg of acarbose; and trials 3 and 4 (T3 and T4), simultaneous intake of starch (150 g of rice) with 50 mg or 100 mg of acarbose, respectively. Fifteen young, healthy women were enrolled. Peak ΔBG occurred at 30 min in both T1 and T2 and at 60 min in T3. ΔBG at 30 min was significantly lower in T3 and T4 than in T2 (both P <.05) without trial order effect, while BG areas under the curve did not differ between T2 and T3. Inhibition of SAA by oral acarbose reduced the early postprandial increase in BG compared with intact SAA activity in healthy individuals.

Source: JMIR Formative Research

DOI: 10.2196/98441

Authors: Airi Sekine, Kei Nakajima

Institutions: Japan Women's University, Social Insurance Saitama Chuo Hospital, Saitama Medical Center, Saitama Medical University, Saitama Medical University

Language: English

Topic: Natural Antidiabetic Agents Studies

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,900